Page last updated: 2024-11-02

piracetam and Alcohol Drinking

piracetam has been researched along with Alcohol Drinking in 12 studies

Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.

Alcohol Drinking: Behaviors associated with the ingesting of ALCOHOLIC BEVERAGES, including social drinking.

Research Excerpts

ExcerptRelevanceReference
"Our data suggest that levetiracetam is not an appropriate treatment for non-treatment seeking alcohol abusers and can, in fact, increase their consumption of alcohol."9.16The anticonvulsant levetiracetam potentiates alcohol consumption in non-treatment seeking alcohol abusers. ( Coker, AR; Grossman, LE; Messing, RO; Mitchell, JM, 2012)
"Our data suggest that levetiracetam is not an appropriate treatment for non-treatment seeking alcohol abusers and can, in fact, increase their consumption of alcohol."5.16The anticonvulsant levetiracetam potentiates alcohol consumption in non-treatment seeking alcohol abusers. ( Coker, AR; Grossman, LE; Messing, RO; Mitchell, JM, 2012)
"This study suggests that levetiracetam deserves further study in the treatment of alcohol dependence and co-occurring anxiety disorders."5.13Levetiracetam for the treatment of co-occurring alcohol dependence and anxiety: case series and review. ( Levin, FR; Mariani, JJ, 2008)
" The increased risk associated with piracetam may reflect awareness of memory problems before any diagnosis of dementia has been made."3.75Sociodemographic and lifestyle risk factors for incident dementia and cognitive decline in the HYVET. ( Beckett, N; Bulpitt, C; de Vernejoul, MC; Fletcher, A; Gainsborough, N; Geneva, M; Lu, FH; Peters, R; Poulter, R; Tzekova, M; Williams, B, 2009)
"Zonisamide is a structurally related anticonvulsant that is a promising agent for the treatment of AD and may have greater tolerability than topiramate."2.80Zonisamide, topiramate, and levetiracetam: efficacy and neuropsychological effects in alcohol use disorders. ( Ciraulo, DA; Colaneri, L; Devine, E; Knapp, CM; Oscar-Berman, M; Putnam, M; Richambault, C; Richardson, MA; Sarid-Segal, O; Streeter, CC; Surprise, C; Waters, M, 2015)
"The findings of this study provide some evidence that levetiracetam is an efficacious and safe treatment option for outpatient alcohol detoxification."1.36Efficacy and safety of levetiracetam for outpatient alcohol detoxification. ( Förg, A; Heimann, HM; Hein, J; Heinz, A; Hinzpeter, A; Müller, CA; Schäfer, M; Schneider, S; Volkmar, K, 2010)
"The enhanced seizure susceptibility after a single dose of ethanol was abolished by piracetam and MGO."1.27Influence of nootropic drugs on drinking behaviour in ethanol-preferring mice and ethanol-induced increase of seizure susceptibility. ( Andreas, K; Dienel, A; Schmidt, J, 1985)

Research

Studies (12)

TimeframeStudies, this research(%)All Research%
pre-19903 (25.00)18.7374
1990's2 (16.67)18.2507
2000's2 (16.67)29.6817
2010's5 (41.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Fish, EW1
Agoglia, AE1
Krouse, MC1
Muller, RG1
Robinson, JE1
Malanga, CJ1
Knapp, CM1
Ciraulo, DA1
Sarid-Segal, O1
Richardson, MA1
Devine, E1
Streeter, CC1
Oscar-Berman, M1
Surprise, C1
Colaneri, L1
Putnam, M1
Waters, M1
Richambault, C1
Mariani, JJ1
Levin, FR1
Peters, R1
Beckett, N1
Geneva, M1
Tzekova, M1
Lu, FH1
Poulter, R1
Gainsborough, N1
Williams, B1
de Vernejoul, MC1
Fletcher, A1
Bulpitt, C1
Müller, CA1
Schäfer, M1
Schneider, S1
Heimann, HM1
Hinzpeter, A1
Volkmar, K1
Förg, A1
Heinz, A1
Hein, J1
Zalewska-Kaszubska, J1
Bajer, B1
Czarnecka, E1
Dyr, W1
Gorska, D1
Mitchell, JM1
Grossman, LE1
Coker, AR1
Messing, RO1
Schmidt, J2
Andreas, K2
Dienel, A2
Fischer, HD1
Wustmann, C1
Genton, P1
Guerrini, R1
Salimov, RM1
Viglinskaia, IV1
Badian, M1
Brettel, HF1
Malerczyk, V1
Ostrowski, J1
Sittig, W1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Double-Blind, Placebo-Controlled, Parallel Group Design Trial of; Levetiracetam, Zonisamide, Topiramate, and Placebo Control for the Treatment of Alcohol Dependent Subjects.[NCT00862563]Phase 285 participants (Actual)Interventional2009-05-31Terminated (stopped due to Recruitment goals could not be met before ending of funding for this project.)
Placebo-Controlled Crossover Trial of Levetiracetam on Ethanol Intake[NCT01168687]46 participants (Actual)Interventional2008-11-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

AB-Neurotoxicity Scale.

Total Scores AB-Neurotoxicity Scale Week 12. This scale provides subject ratings of anticonvulsant neurotoxic effects. Scores may range 0 to 72, with possibility of an additional 30 points being for complaints not listed in the list of complaints provides. Total scores, therefore, may be as high as 102, with higher scores indicating greater severity of problems. Actual mean scores are shown. Means for the analysis are least means squares values obtained from a two-way repeated measures mixed models analysis, with Week (time) as the the within subject factor and treatment as the between group factor. Baseline values were used as covariates. (NCT00862563)
Timeframe: Week 12

InterventionScale Scores (Mean)
Zonisamide7.1
Levetiracetam11.3
Topiramate15.4
Sugar Pill5.8

Controlled Word Association Test (COWAT)- Letter Fluency

Number of words generated that start with a set of 3 letters. The COWAT provides a measure of verbal fluency. Actual means for COWAT results are shown. (NCT00862563)
Timeframe: Baseline & Week 12

,,,
InterventionNumber of Words Produced (Mean)
BaselineWeek 12
Levetiracetam46.245.4
Sugar Pill47.450.5
Topiramate43.428.1
Zonisamide46.532.5

COWAT-Category

Number of words produced by subjects over 60 seconds for a semantic category (Animals). The COAWAT-Category sub-test provides a measure of verbal fluency. Mean value shown are actual means for the number of words produced. (NCT00862563)
Timeframe: Baseline, Week12

,,,
InterventionNumber of Words Produced (Mean)
BaselineWeek 12
Levetiracetam20.921.2
Sugar Pill21.620.8
Topiramate21.917.0
Zonisamide22.617.4

Mean Percent Days Heavy Drinking

Mean weekly values for each treatment group for percent days heavy drinking. Heavy drinking was defined as 4 or more drinks per day for women and 5 or more drinks per day for men. (NCT00862563)
Timeframe: Weeks 10, 11, 12

,,,
InterventionPercentage of Days/Week (Mean)
Week 10Week 11Week 12
Levetiracetam49.647.944.5
Sugar Pill65.761.760.9
Topiramate32.129.521.0
Zonisamide38.436.634.3

Percent Days Drinking

Mean percent days drinking for Weeks 10, 11, 12. A drinking day is considered to be a day in which 1 or more drinks have been consumed. Means are model generated least means squares values obtained from a two-way repeated measures analysis from data obtained from Weeks 1 through 12, with Week as the within subject factor and treatment group as the between group factor. (NCT00862563)
Timeframe: Weeks 10, 11, 12

,,,
InterventionPercentage of Days/ Week (Mean)
Week 10Week 11Week 12
Levetiracetam72.268.973.1
Sugar Pill83.687.278.2
Topiramate51.843.851.4
Zonisamide61.662.161.3

The Primary Efficacy Measure is the Mean Number of Drinks Consumed Per Day Over the Period From Treatment Weeks 10 Through 12 When All Study Medications Should be at Their Maximum Steady Levels Based on Their Known Pharmacokinetic Properties.

Mean standard drinks consumed per day for each treatment week, weeks 10 thru 12. Actual mean values obtained are shown. Analyses are based on model generated least squares means for a two -way repeated measures mixed models analysis for data obtained for weeks 1 through 12, with baseline values used as covariates. Week (time) was used as the within subject factor and treatment group was the between group factor. (NCT00862563)
Timeframe: Weeks 10, 11, 12

,,,
InterventionStandard Drinks per day (Mean)
Week 10Week 11Week 12
Levetiracetam4.64.34.3
Sugar Pill6.36.86.0
Topiramate3.22.72.5
Zonisamide3.83.42.5

Wechsler Memory Scale-3rd Ed. Spatial Span

WMS Spatial Span test measures working memory for a spatial sequence of numbers. This assesses visual working memory. Age adjusted scaled scores are presented. Score may range between 1 and 19, with lower scores indicating greater impairment in performance. (NCT00862563)
Timeframe: Baseline, Week 12

,,,
Interventionunits on a scale (Mean)
BaselineWeek 12
Levetiracetam10.510.9
Sugar Pill10.810.4
Topiramate12.08.4
Zonisamide10.87.9

Wechsler Memory Scales (WMS)-3d Ed Digit Span-Age Adjusted Total

WMS Digit Span is a measure of working memory. Subjects respond by repeating lists of number sequences presented by the test administrator. Age adjusted scores are presented below. Scores may range between 1 and 19, with lower scores indicating poorer performance on the task. (NCT00862563)
Timeframe: Baseline, Week 12

,,,
Interventionunits on a scale (Mean)
BaselineWeek 12
Levetiracetam11.912.2
Sugar Pill12.613.0
Topiramate12.17.7
Zonisamide11.810.0

Standard Alcoholic Drinks Per Treatment Period

The primary outcome of this study is to determine the effect of levetiracetam on alcohol consumption as measured by change in # of drinks during each treatment period. (NCT01168687)
Timeframe: During each 14 day treatment period

Interventionnumber of drinks per treatment period (Mean)
All Subjects (n = 46) Placebo41.2
All Subjects (n = 46) Levetiracetam45.4

Trials

3 trials available for piracetam and Alcohol Drinking

ArticleYear
Zonisamide, topiramate, and levetiracetam: efficacy and neuropsychological effects in alcohol use disorders.
    Journal of clinical psychopharmacology, 2015, Volume: 35, Issue:1

    Topics: Adult; Aged; Alcohol Drinking; Alcohol-Related Disorders; Anticonvulsants; Cognition Disorders; Doub

2015
Levetiracetam for the treatment of co-occurring alcohol dependence and anxiety: case series and review.
    The American journal of drug and alcohol abuse, 2008, Volume: 34, Issue:6

    Topics: Adult; Alcohol Drinking; Alcoholism; Anxiety Disorders; Diagnosis, Dual (Psychiatry); Female; Humans

2008
The anticonvulsant levetiracetam potentiates alcohol consumption in non-treatment seeking alcohol abusers.
    Journal of clinical psychopharmacology, 2012, Volume: 32, Issue:2

    Topics: Alcohol Drinking; Alcoholism; Anticonvulsants; Cross-Over Studies; Dose-Response Relationship, Drug;

2012

Other Studies

9 other studies available for piracetam and Alcohol Drinking

ArticleYear
Levetiracetam results in increased and decreased alcohol drinking with different access procedures in C57BL/6J mice.
    Behavioural pharmacology, 2014, Volume: 25, Issue:1

    Topics: Alcohol Drinking; Animals; Anticonvulsants; Central Nervous System Depressants; Choice Behavior; Dos

2014
Sociodemographic and lifestyle risk factors for incident dementia and cognitive decline in the HYVET.
    Age and ageing, 2009, Volume: 38, Issue:5

    Topics: Aged, 80 and over; Aging; Alcohol Drinking; Antihypertensive Agents; Cognition Disorders; Dementia;

2009
Efficacy and safety of levetiracetam for outpatient alcohol detoxification.
    Pharmacopsychiatry, 2010, Volume: 43, Issue:5

    Topics: Adolescent; Adult; Aged; Alcohol Drinking; Alcoholism; Ambulatory Care; Anticonvulsants; Female; Hum

2010
Voluntary alcohol consumption and plasma beta-endorphin levels in alcohol preferring rats chronically treated with levetiracetam: a preliminary study.
    Physiology & behavior, 2011, Mar-28, Volume: 102, Issue:5

    Topics: Alcohol Drinking; Alcoholism; Animals; Anticonvulsants; beta-Endorphin; Disease Models, Animal; Dose

2011
Ethanol preference behaviour and dopamine release in the rat.
    Biomedica biochimica acta, 1984, Volume: 43, Issue:12

    Topics: Alcohol Drinking; Amphetamines; Animals; Behavior, Animal; Corpus Striatum; Dopamine; Food Preferenc

1984
Effect of alcohol on action myoclonus in Lance-Adams syndrome and progressive myoclonus epilepsy.
    Movement disorders : official journal of the Movement Disorder Society, 1992, Volume: 7, Issue:1

    Topics: Alcohol Drinking; Drug Tolerance; Epilepsies, Myoclonic; Follow-Up Studies; Humans; Myoclonus; Pirac

1992
[Evaluation of accelerated development of stable alcoholic motivation in rats for studying potential alcohol deterrents].
    Biulleten' eksperimental'noi biologii i meditsiny, 1990, Volume: 109, Issue:4

    Topics: Alcohol Deterrents; Alcohol Drinking; Alcoholism; Animals; Carbazoles; Ethanol; Male; Motivation; Pi

1990
[Combination of alcohol and piracetam].
    Blutalkohol, 1987, Volume: 24, Issue:5

    Topics: Adult; Alcohol Drinking; Arousal; Drug Interactions; Humans; Male; Piracetam; Postural Balance; Psyc

1987
Influence of nootropic drugs on drinking behaviour in ethanol-preferring mice and ethanol-induced increase of seizure susceptibility.
    Biomedica biochimica acta, 1985, Volume: 44, Issue:5

    Topics: Alcohol Drinking; Alcoholism; Animals; Dihydroergotoxine; Ethanol; Male; Meglumine; Mice; Mice, Inbr

1985